Back to discover

Protein / target

Protein kinase C eta type

Encoded byPRKCHP24723Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Diacylglycerol-dependent serine/threonine kinase

Strongest disease association

Ischemic Stroke

Via encoding gene PRKCH · Genetic literature evidence · score 0.61

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in the regulation of cell differentiation in keratinocytes and pre-B cell receptor, mediates regulation of epithelial tight junction integrity and foam cell formation, and is requir…

View complete UniProt function annotation

Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in the regulation of cell differentiation in keratinocytes and pre-B cell receptor, mediates regulation of epithelial tight junction integrity and foam cell formation, and is required for glioblastoma proliferation and apoptosis prevention in MCF-7 cells. In keratinocytes, binds and activates the tyrosine kinase FYN, which in turn blocks epidermal growth factor receptor (EGFR) signaling and leads to keratinocyte growth arrest and differentiation. Associates with the cyclin CCNE1-CDK2-CDKN1B complex and inhibits CDK2 kinase activity, leading to RB1 dephosphorylation and thereby G1 arrest in keratinocytes. In association with RALA activates actin depolymerization, which is necessary for keratinocyte differentiation. In the pre-B cell receptor signaling, functions downstream of BLNK by up-regulating IRF4, which in turn activates L chain gene rearrangement. Regulates epithelial tight junctions (TJs) by phosphorylating occludin (OCLN) on threonine residues, which is necessary for the assembly and maintenance of TJs. In association with PLD2 and via TLR4 signaling, is involved in lipopolysaccharide (LPS)-induced RGS2 down-regulation and foam cell formation. Upon PMA stimulation, mediates glioblastoma cell proliferation by activating the mTOR pathway, the PI3K/AKT pathway and the ERK1-dependent phosphorylation of ELK1. Involved in the protection of glioblastoma cells from irradiation-induced apoptosis by preventing caspase-9 activation. In camptothecin-treated MCF-7 cells, regulates NF-kappa-B upstream signaling by activating IKBKB, and confers protection against DNA damage-induced apoptosis. Promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Phosphorylates ATF2 which promotes its nuclear retention and transcriptional activity and negatively regulates its mitochondrial localization

Subcellular location

Cytoplasm
Domains and Gene Ontology detail (29)

Domains & features

C2Protein kinaseAGC-kinase C-terminal

Gene Ontology

  • Ccell-cell junction
  • Ccytoplasm
  • Ccytosol
  • Cextracellular exosome
  • Cplasma membrane
  • FATP binding
  • Fdiacylglycerol-dependent serine/threonine kinase activity
  • Fdiacylglycerol-dependent, calcium-independent serine/threonine kinase activity
  • Fenzyme binding
  • Fprotein kinase activity
  • Fprotein serine kinase activity
  • Fprotein serine/threonine kinase activity

683 aa · 78 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Growth-factor signallingUniProtOncogenic signallingUniProtLipid & lipoprotein metabolismUniProtKinase signallingUniProt · GOCell adhesionUniProt · GOImmune signallingUniProt · GO
View supporting evidence

Growth-factor signalling

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…

Oncogenic signalling

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…

Lipid & lipoprotein metabolism

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…

Kinase signalling

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…
  • ·diacylglycerol-dependent serine/threonine kinase activity
  • ·diacylglycerol-dependent, calcium-independent serine/threonine kinase activity
  • ·protein kinase activity

Cell adhesion

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…
  • ·cell-cell junction
  • ·regulation of bicellular tight junction assembly

Immune signalling

  • ·Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-p…
  • ·positive regulation of B cell receptor signaling pathway

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 4 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Leukemia, Myeloid, Acute1 medicine
Mastocytosis1 medicine
Mastocytosis, Systemic1 medicine
Broader indication categories (1)
Neoplasms1 medicine

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

midostaurin
ApprovedInhibitor

Protein kinase C (PKC) inhibitor

Indicated for Leukemia, Myeloid, Acute, Mastocytosis, Mastocytosis, Systemic, Neoplasms

Acts on a complex — shared with PRKD3, PRKCI, PRKCA +7 more · 1 of 16 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PRKCH

Gene-level evidence surfaced through the gene PRKCH that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Leukemia, Myeloid, Acute
0.68Moderately supported

Clinical evidence dominant · Open Targets 0.55

Neoplasms
0.53Moderately supported

Clinical evidence dominant · Open Targets 0.40

Ischemic Stroke
0.51Moderately supported

Genetic literature evidence dominant · Open Targets 0.40

Neurodegenerative Diseases
0.32Preliminary

Pathway evidence dominant · Open Targets 0.48 · no direct causal or clinical evidence

View evidence synthesis (4)
Leukemia, Myeloid, AcuteModerately supported
0.68
agreement 0.520.83
Clinical96%Literature4%

Open Targets aggregate 0.55 · 2 independent evidence families

NeoplasmsModerately supported
0.53
agreement 0.370.68
Clinical81%Literature19%

Open Targets aggregate 0.40 · 2 independent evidence families

Ischemic StrokeModerately supported
0.51
agreement 0.360.66
Genetic literature91%Literature9%Geneticdup

Open Targets aggregate 0.40 · 2 independent evidence families · 1 not counted as duplicate

Neurodegenerative DiseasesPreliminary
0.32
agreement 0.090.55
Pathway100%

Open Targets aggregate 0.48 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Leukemia, Myeloid, Acute0.55
Neurodegenerative Diseases0.48
Ischemic Stroke0.40
Neoplasms0.40

Drug development

5 compounds recorded · 1 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (5)
GSK-690693Phase 1
MIDOSTAURINApproval
CEP-2563Phase 1
UCN-01Phase 2
SOTRASTAURINPhase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf and human protein atlas loc) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (9)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · GO CC high confAB · Human Protein Atlas locPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ClinicalTrials.gov via the drug-target graph.

What's happening now

3

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2017-09-18

    Approval: Rydapt (EMA)

    ema · regulatory · ema · via midostaurin

  2. New publication2017-07-24
    Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.

    Leukemia · 2018 · 109 citations · Europe PMC · via midostaurin

  3. New publication2016-06-01
    Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

    The New England journal of medicine · 2016 · 371 citations · Europe PMC · via midostaurin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.